Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
39.91
+0.45 (1.14%)
At close: Jul 3, 2025, 1:00 PM
39.20
-0.71 (-1.78%)
After-hours: Jul 3, 2025, 4:53 PM EDT
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 15 analysts that cover Ultragenyx Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $90.53, which forecasts a 126.84% increase in the stock price over the next year. The lowest target is $48 and the highest is $140.
Price Target: $90.53 (+126.84%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 5 |
| Buy | 8 | 8 | 8 | 10 | 9 | 9 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 17 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $64 | Strong Buy | Reiterates | $64 | +60.36% | Jun 20, 2025 |
| William Blair | William Blair | Buy Initiates $65 | Buy | Initiates | $65 | +62.87% | May 28, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $64 → $65 | Buy | Maintains | $64 → $65 | +62.87% | May 9, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $104 → $117 | Buy | Maintains | $104 → $117 | +193.16% | Mar 27, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $140 → $115 | Buy | Maintains | $140 → $115 | +188.15% | Mar 17, 2025 |
Financial Forecast
Revenue This Year
666.34M
from 560.23M
Increased by 18.94%
Revenue Next Year
859.12M
from 666.34M
Increased by 28.93%
EPS This Year
-5.07
from -6.29
EPS Next Year
-3.59
from -5.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 702.8M | 1.1B | 1.8B | ||
| Avg | 666.3M | 859.1M | 1.3B | ||
| Low | 620.0M | 684.5M | 783.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.5% | 60.4% | 110.4% | ||
| Avg | 18.9% | 28.9% | 46.8% | ||
| Low | 10.7% | 2.7% | -8.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.85 | -0.86 | 1.56 | ||
| Avg | -5.07 | -3.59 | -0.94 | ||
| Low | -6.89 | -5.27 | -3.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.